Bristol-Myers multiple myeloma data boosts C4 (BMY:NYSE)
· seekingalpha.com
C4 Therapeutics (CCCC) stock gains as Bristol-Myers Squibb's (BMY) multiple myeloma drug, similar to company's lead asset, generates strong trial data. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...